Lanfranco Pellesi

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 23

Top Venues

Expert opinion on emerging drugs

Expert opinion on pharmacotherapy

Expert opinion on drug discovery

Pain practice : the official journal of World Institute of Pain

University of Copenhagen

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Copenhagen Nov 01 2019

Denmark

PhD student :: Department of Neuroscience

Publications

Lanfranco Pellesi, Messoud Ashina, Paolo Martelletti
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. Expert opinion on emerging drugs (2024)
Lanfranco Pellesi, Messoud Ashina, Paolo Martelletti
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. Expert opinion on emerging drugs 29 (1) (2024)
Lanfranco Pellesi, Thien Phu Do, Anders Hougaard
Pharmacological management of migraine: current strategies and future directions. Expert opinion on pharmacotherapy 25 (6) (2024)
Lanfranco Pellesi, Paolo Martelletti
Situational prevention in migraine: are we doing the right thing? The journal of headache and pain 25 (1) (2024)
Lanfranco Pellesi, Thien Phu Do, Anders Hougaard
Pharmacological management of migraine: current strategies and future directions. Expert opinion on pharmacotherapy 25 (6) (2024)
Lanfranco Pellesi, Thien Phu Do, Anders Hougaard
Pharmacological management of migraine: current strategies and future directions. Expert opinion on pharmacotherapy (2024)
Lanfranco Pellesi, Messoud Ashina, Paolo Martelletti
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. Expert opinion on emerging drugs (2024)
Lanfranco Pellesi, Paolo Martelletti
Situational prevention in migraine: are we doing the right thing? The journal of headache and pain 25 (1) (2024)
Carlo Baraldi, Dagmar Beier, Paolo Martelletti, Lanfranco Pellesi
The preclinical discovery and development of atogepant for migraine prophylaxis. Expert opinion on drug discovery (2024)
Laura Nedergaard, Maria Celine Martens, Michala Daniela Bach Christensen, Lanfranco Pellesi
Triptan treatment is associated with a higher number of red wine-induced migraine episodes: An exploratory questionnaire-based survey. Pain practice : the official journal of World Institute of Pain (2024)
William David Wells-Gatnik, Lanfranco Pellesi, Paolo Martelletti
Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. Expert review of neurotherapeutics (2024)
Carlo Baraldi, Dagmar Beier, Paolo Martelletti, Lanfranco Pellesi
The preclinical discovery and development of atogepant for migraine prophylaxis. Expert opinion on drug discovery 19 (7) (2024)
Laura Nedergaard, Maria Celine Martens, Michala Daniela Bach Christensen, Lanfranco Pellesi
Triptan treatment is associated with a higher number of red wine-induced migraine episodes: An exploratory questionnaire-based survey. Pain practice : the official journal of World Institute of Pain 24 (6) (2024)
Lanfranco Pellesi, Messoud Ashina, Paolo Martelletti
Targeting the PACAP-38 pathway is an emerging therapeutic strategy for migraine prevention. Expert opinion on emerging drugs 29 (1) (2024)
Lanfranco Pellesi
The human NTG model of migraine in drug discovery and development. Expert opinion on drug discovery (2023)
Lanfranco Pellesi, Basit Ali Chaudhry, Anne Luise Haulund Vollesen, Agneta Henriette Snoer, Katrine Baumann, Per Stahl Skov, Rigmor Højland Jensen, Messoud Ashina
PACAP38- and VIP-induced cluster headache attacks are not associated with changes of plasma CGRP or markers of mast cell activation. Cephalalgia : an international journal of headache (2021)
Flavia Lo Castro, Simona Guerzoni, Lanfranco Pellesi
Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review. Drug, healthcare and patient safety 13 (2021)
Lanfranco Pellesi, Roberto De Icco, Mohammad Al-Mahdi Al-Karagholi, Messoud Ashina
Reducing Episodic Cluster Headaches: Focus on Galcanezumab. Journal of pain research 13 (2020)
Lanfranco Pellesi, Thien P Do, Håkan Ashina, Anne Luise Haulund Vollesen, Rami Burstein
Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale? Headache 60 (6) (2020)
Lanfranco Pellesi, Maria Chiara Verga, Nicola De Maria, Erica Villa, Luigi Alberto Pini, Simona Guerzoni
Nabilone administration in refractory chronic diarrhea: a case series. BMC gastroenterology 19 (1) (2019)
Lanfranco Pellesi, Sabina Cevoli, Valentina Favoni, Chiara Lupi, Edoardo Mampreso, Andrea Negro, Antonio Russo, Silvia Benemei, Simona Guerzoni
Nummular headache: a gender-oriented perspective on a case series from the RegistRare Network. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 41 (3) (2019)
Lanfranco Pellesi, Elisa Bellei, Simona Guerzoni, Maria Michela Cainazzo, Carlo Baraldi, Emanuela Monari, Luigi Alberto Pini
Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication-overuse headache. BMC neurology 19 (1) (2019)
Lanfranco Pellesi, Manuela Licata, Patrizia Verri, Daniele Vandelli, Federica Palazzoli, Filippo Marchesi, Maria Michela Cainazzo, Luigi Alberto Pini, Simona Guerzoni
Pharmacokinetics and tolerability of oral cannabis preparations in patients with medication overuse headache (MOH)-a pilot study. European journal of clinical pharmacology 74 (11) (2018)

Lanfranco Pellesi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Lanfranco Pellesi